Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma

Annals of Hematology

Volumn 88, Issue 9, 2009, Pages 921-922

  Tempescul, Adrian ^a   Ianotto, Jean Christophe ^a   Morel, Frederic ^b   Marion, Veronique ^a   Braekeleer, Marc ^b   Berthou, Christian ^a  

^a CHU MORVAN   (France)

^b FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; CHLORAMBUCIL; CYCLIN D1; DEXAMETHASONE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; LENALIDOMIDE; RITUXIMAB; VINCRISTINE;

AGED; ASTHENIA; B LYMPHOCYTE; BLOOD CELL COUNT; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYTOPENIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; GENE OVEREXPRESSION; GENE TRANSLOCATION; GENETIC ANALYSIS; HUMAN; LETTER; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOSIS; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHENOTYPE; PRIORITY JOURNAL; SPLENOMEGALY;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; RECURRENCE; REMISSION INDUCTION; THALIDOMIDE;

EID: 67849090899     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0692-4     Document Type: Letter

References (11)

1. Campo E, Raffeld M, Jaffe ES (1999) Mantle-cell lymphoma. Semin Hematol 36(2):115-127 (review)
2. Goy A (2007) Mantle cell lymphoma: Evolving novel options. Curr Oncol Rep 9(5):391-398 (review), doi: 10.1007/s11912-007-0053-9
3. Manabe A, Murti KG, Coustan-Smith E, Kumagai M, Behm FG, Raimondi SC, Campana D (1994) Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. Blood 83(3):758-766
4. Merville P, Déchanet J, Desmoulière A, Durand I, de Bouteiller O, Garrone P, Banchereau J, Liu YJ (1996) -Bcl-2+ tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts. J Exp Med 183(1):227-236. doi: 10.1084/jem.183.1.227
5. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163(1):380-386
6. Settles B, Stevenson A, Wilson K, Mack C, Ezell T, Davis MF, Taylor LD (2001) Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol Biol 47(7):1105-1114
7. Kaufmann H, Raderer M, Wöhrer S, Püspök A, Bankier A, Zielinski C, Chott A, Drach J (2004) Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 104(8):2269-2271. doi: 10.1182/blood-2004-03-1091
8. Damaj G, Lefrère F, Delarue R, Varet B, Furman R, Hermine O (2003) Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia 17(9):1914-1915. doi: 10.1038/sj.leu.2403058
9. Wilson EA, Jobanputra S, Jackson R, Parker AN, McQuaker IG (2002) Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report. Br J Haematol 119(1):128-130. doi: 10.1046/ j.1365-2141.2002.03810.x
10. Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, Cheson BD, Cancer and Leukemia Group B (2008) Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: A phase II trial of the Cancer and Leukemia Group B. Br J Haematol 140(3):313-319. doi: 10.1111/j.1365-2141.2007.06937.x
11. Wang M, Fayad L, Hegemeister F et al (2007) A phase I/II study of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma with early evidence of efficacy. J Clin Oncol 25:8030